ELN valuation could be $30 billion with Antegren and two Alzheimers drugs in the pipeline. The three most important things for a high valuation to a drug company with lots of cash is Pipeline, Pipeline, and Pipeline. Let's not forget that Elan has lots of cash and is raising more CASH.
PS: How about that Pipeline with Antegren, Two Alzheimers drugs, Frova, Prialt, plus many JVs.
>>ELN valuation could be $30 billion with Antegren and two Alzheimers drugs in the pipeline.<<
Much as I wish this were true, this is pure bunk. To achieve $30B valuation, Elan will need to have $3B in sales and have a strong pipeline.
>>Let's not forget that Elan has lots of cash and is raising more CASH.<<
Let's not forget that this cash is more than already spoken for: $800MM in LYONs can be put at end of year and $840MM in EPIL II and III debt is due next year and the year after. Plus, add in $250MM in annual operating losses over the next 2 years...
DEBT: EPIL II & III - $840MM LYONS - $800MM
OPERATING LOSS EST.: $250MM
I hope that operating losses are offset by increased Frova sales, and myobloc sales and by Prialt and Antegren sales (assuming approval). But who is going to sell these products now?...